MCL1 and osteosarcoma: While the exact molecular mechanism of TOPK inhibition in osteosarcoma is unclear, we report a marked decrease in the antiapoptotic proteins Mcl‐1 and Survivin alongside increased apoptotic cleavage of PARP.